The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01.

The partnership is expected to yield treatments that demonstrate efficacy and offer improved quality of life and tolerability ...

Proxygen GmbH has divulged molecular glue degraders comprising a cullin-ring E3 ligase (CRL)-binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be ...

Genentech Inc. has disclosed molecular glue compounds with the ability to induce cyclin-dependent kinase 2 (CDK2)/protein cereblon (CRBN) interaction for CDK2 degradation reported to be useful for the ...

AKT regulates the cell cycle by phosphorylating FoxO1 and decreasing its transcription of CDK inhibitors p21 and p27. AKT, protein kinase B; CDK, cyclin dependent kinase; FoxO1, forkhead box O1 ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Shares in US biotech Arvinas were more than 50% lower, and those in pharma giant Pfizer down 2%, at the mid-point of ...